AstraZeneca PLC Directorate Change (0735A)
25 Settembre 2020 - 8:00AM
UK Regulatory
TIDMAZN
RNS Number : 0735A
AstraZeneca PLC
25 September 2020
25 September 2020 07:00 BST
Non-Executive Board Appointment
AstraZeneca PLC today announced that with effect from 1 October
2020, Dr Euan Ashley is appointed as a Non-Executive Director and a
member of the Science Committee.
Leif Johansson, Chairman of AstraZeneca, said: "We look forward
to welcoming Euan to AstraZeneca and believe his scientific
achievements and interests, which are well-aligned with our own
BioPharmaceuticals R&D, together with his entrepreneurial
experience on the US west coast will enable him to make a
significant contribution to the Board's work."
Euan Ashley is Associate Dean and Professor of Cardiovascular
Medicine and Genetics at Stanford University in California. Dr
Ashley's research focuses on genetic mechanisms of cardiovascular
health and disease. In addition to wet bench science, his
laboratory leverages artificial intelligence and digital health
tools, working with biotechnology and technology partners in
Silicon Valley, to advance both translational and clinical
research.
Dr Ashley studied physiology and medicine at Glasgow University,
completing his junior doctor training at Oxford University
Hospitals NHS Trust, before undertaking a DPhil in cardiovascular
cellular biology and molecular genetics at the University of
Oxford. In 2002, he moved to Stanford University to train in
cardiology and advanced heart failure.
Dr Ashley has received many awards including recognition from
the Obama White House for contributions to personalized medicine
and the American Heart Association's Medal of Honor for precision
medicine.
No disclosure obligations arise under paragraphs (1) to (6) of
LR 9.6.13 R of the UK Listing Authority's Listing Rules in respect
of this appointment.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development and commercialisation of prescription medicines,
primarily for the treatment of diseases in three therapy areas -
Oncology, Cardiovascular, Renal & Metabolism, and Respiratory
& Immunology. Based in Cambridge, UK, AstraZeneca operates in
over 100 countries and its innovative medicines are used by
millions of patients worldwide. Please visit astrazeneca.com and
follow the Company on Twitter @ AstraZeneca .
Contacts
For details on how to contact the Investor Relations Team,
please click here . For Media contacts, click here .
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOASELESLESSEIU
(END) Dow Jones Newswires
September 25, 2020 02:00 ET (06:00 GMT)
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Apr 2023 a Apr 2024